一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Single-cell sequencing of tumour infiltrating T cells efficiently identifies tumour-specific T cell receptors based on the T cell activation score.
Single-cell sequencing of tumour infiltrating T cells efficiently identifies tumour-specific T cell receptors based on the T cell activation score.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
过继转移的T细胞受体工程化T细胞是一种有前景的癌症治疗策略,而肿瘤特异性TCR的鉴定至关重要。既往研究报道,可基于活化标志物的表达分离肿瘤反应性T细胞和TCR。
然而,由于不同细胞状态的T细胞对活化的反应并不一致,而是表现出活化和效应分子的异质性表达谱,因此基于单一活化或效应分子分离肿瘤反应性T细胞可能导致肿瘤反应性T细胞的缺失;因此,联合多种活化和效应分子可提高分离肿瘤特异性TCR的效率。
我们入组了两例肺腺癌患者,并获取了其TIL(肿瘤浸润淋巴细胞)(TILs)和自体肿瘤细胞(ATCs)。将TILs与相应的ATCs共培养12 h,并进行单细胞RNA测序。首先,我们为每例患者鉴定了IFNG和TNFRSF9 mRNA表达水平最高的三个TCR,但每例患者中仅排名第一或第二的TCR能够识别相应的ATCs。接下来,我们根据每个T细胞中IFNG、IL2、TNF、IL2RA、CD69、TNFRSF9、GZMB、GZMA、GZMK和PRF1 mRNA的归一化表达水平定义了活化评分,然后为每例患者鉴定了活化评分最高的三个TCR。
我们发现,每例患者中所有三个TCR均能特异性识别相应的ATCs。总之,我们建立了一种通过单细胞RNA测序基于多种活化和效应分子组合分离肿瘤反应性TCR的高效方法。
Adoptively transferred T cell receptor-engineered T cells are a promising cancer treatment strategy, and the identification of tumour-specific TCRs is essential. Previous studies reported that tumour-reactive T cells and TCRs could be isolated based on the expression of activation markers.
However, since T cells with different cell states could not respond uniformly to activation but show a heterogeneous expression profile of activation and effector molecules, isolation of tumour-reactive T cells based on single activation or effector molecules could result in the absence of tumour-reactive T cells; thus, combinations of multiple activation and effector molecules could improve the efficiency of isolating tumour-specific TCRs.
We enrolled two patients with lung adenocarcinoma and obtained their tumour infiltrating lymphocytes (TILs) and autologous tumour cells (ATCs). TILs were cocultured with the corresponding ATCs for 12 h and subjected to single-cell RNA sequencing. First, we identified three TCRs with the highest expression levels of IFNG and TNFRSF9 mRNA for each patient, yet only the top one or two recognized the corresponding ATCs in each patient.
Next, we defined the activation score based on normalized expression levels of IFNG, IL2, TNF, IL2RA, CD69, TNFRSF9, GZMB, GZMA, GZMK, and PRF1 mRNA for each T cell and then identified three TCRs with the highest activation score for each patient.
We found that all three TCRs in each patient could specifically identify corresponding ATCs.
In conclusion, we established an efficient approach to isolate tumour-reactive TCRs based on combinations of multiple activation and effector molecules through single-cell RNA sequencing.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。